Core Insights - HeartSciences Inc. has submitted its MyoVista® wavECG™ device to the FDA for 510(k) premarket clearance, marking a significant regulatory milestone in its commercialization strategy [1][2] Company Overview - HeartSciences is a healthcare information technology company focused on enhancing ECG/EKG usage through artificial intelligence integration [3] - The MyoVista Insights platform is a next-generation ECG management system designed to improve clinical efficiency and decision-making [3] Product Details - The MyoVista wavECG device offers conventional ECG functionality and is capable of hosting AI-ECG algorithms [2] - The company has opted to separate the FDA submissions for the MyoVista wavECG device and its AI-ECG software algorithm to align with updated clinical standards and expedite the regulatory review process [2] Strategic Developments - The separation of submissions is intended to simplify the regulatory pathway and accelerate device clearance while allowing for future deployment of the AI-ECG algorithm across multiple platforms [2] - The company is making progress with its MyoVista Insights platform and is engaged in commercial discussions with healthcare institutions, expecting to announce initial customer deployments soon [2]

Core Insights - HeartSciences Inc. has announced the commercial release of MyoVista Insights™ version 1.1, enhancing usability and clinical interpretation capabilities of ECG systems [1][2] - The platform is designed to improve workflow efficiency and expand interoperability across various ECG devices, making it a vendor and device agnostic solution [2][3] Product Features - MyoVista Insights is a cloud-native ECG management system that integrates AI ECG algorithm models from multiple partners, streamlining data management and improving workflow efficiency [2] - The updated version 1.1 provides a more intuitive platform for cardiac care, allowing clinicians to quickly interpret complex ECG data and make informed decisions [3] Market Position - Since its launch in May 2025, MyoVista Insights has received strong validation from early adopters and is currently in commercial discussions with several leading healthcare institutions [2] - The company aims to announce key customer deployments in the near term, indicating a positive market reception and potential growth opportunities [2]

Core Viewpoint - HeartSciences Inc. (HSCS) has shown a downtrend recently, with an 8.3% loss over the past two weeks, but a hammer chart pattern suggests a potential trend reversal as buying interest may be emerging [1][2]. Technical Analysis - The hammer chart pattern indicates a possible bottoming out, suggesting that selling pressure may be subsiding [2][5]. - This pattern forms when a stock opens lower, makes a new low, but then closes near or above the opening price, indicating that bulls may be gaining control [4][5]. - Hammer candles can appear on various timeframes and are utilized by both short-term and long-term investors [5]. Fundamental Analysis - There is a strong consensus among Wall Street analysts to raise earnings estimates for HSCS, which supports the bullish case for the stock [2][7]. - The consensus EPS estimate for the current year has increased by 57.4% over the last 30 days, indicating analysts' agreement on the company's improved earnings potential [8]. - HSCS holds a Zacks Rank of 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks, which typically outperform the market [9][10].

Financial Performance - HeartSciences Inc. reported financial results for the quarter ended July 31, 2025, with a focus on operational performance and business updates[7]. - The report does not include specific financial metrics or performance indicators, as the detailed results are provided in the press release[8]. Company Classification - The company is classified as an emerging growth company under the Securities Act of 1933[6]. Stock Information - A press release detailing the financial and operational results was issued on September 11, 2025[7]. - The company's common stock and warrants are traded on The Nasdaq Stock Market LLC under the symbols HSCS and HSCSW, respectively[5].

Core Insights - HeartSciences Inc. reported significant advancements in the first quarter of fiscal 2026, including the FDA Breakthrough Device Designation and the launch of MyoVista Insights, an AI-powered ECG management platform [2][5][8] Financial Performance - For FQ1 2026, HeartSciences reported no meaningful revenue, with approximately $2.8 million in cash and cash equivalents and $3.1 million in shareholders' equity as of July 31, 2025 [9][10] - The company raised an additional $0.8 million through a Reg A+ offering and converted $0.7 million of debt into equity, enhancing its financial position [9] Product Development - MyoVista Insights is a cloud-native software platform aimed at modernizing ECG management systems and facilitating access to AI-ECG algorithms without the need for new ECG devices [6][11] - The platform is designed to integrate with existing ECG hardware and clinical workflows, with CPT reimbursement codes approved by CMS to support AI-ECG adoption [6] - The MyoVista wavECG device is set to host AI-ECG algorithms and is on track for FDA 510(k) submission within the current calendar year [6] Regulatory and Market Position - The FDA granted Breakthrough Device designation for HeartSciences' aortic stenosis ECG algorithm, validating the company's AI-ECG opportunity [5][8] - The company plans to update its algorithms in response to new guidelines from the American Society of Echocardiography, which may enhance its commercial value [6] Intellectual Property - HeartSciences expanded its intellectual property portfolio, holding 44 granted patents worldwide, including a key U.S. patent for estimating echocardiographic parameters via ECG [7]

Financial Performance - Revenues for the three months ended July 31, 2025, were $2,000, with a cost of sales of $1,000, resulting in a gross margin of $1,000 [193]. - The Company incurred a net loss of $2.1 million for the period ended July 31, 2025, with an accumulated deficit of $78.2 million [198]. - Cash and cash equivalents increased to approximately $2.8 million as of July 31, 2025, up from $1.1 million as of April 30, 2025 [205]. - Net cash used in operating activities was $1.9 million during the three months ended July 31, 2025, primarily due to the net loss [207]. - Net cash provided by financing activities was $3.6 million during the three months ended July 31, 2025, primarily from the issuance of Series D Preferred Stock and warrants [209]. Research and Development - The company is focused on developing AI and innovative software technology to enhance the clinical usefulness of ECGs, aiming to provide modernized ECG solutions for a broader range of heart disease detection [155]. - Phase 1 of the MyoVista Insights Cloud Platform has been launched, with expected revenue from installation fees and SaaS-based usage fees, adopting a recurring subscription revenue model for AI-ECG algorithms [157]. - The company has been granted a foundational patent covering the estimation of echocardiography parameters indicative of heart function using an ECG in June 2025 [175]. - Research and development expenses decreased by $228,000, or 19%, to $997,000 for the three months ended July 31, 2025, primarily due to reduced cloud consulting costs [194]. Regulatory and Compliance - The company received FDA "Breakthrough Device" designation for its aortic stenosis ECG algorithm in June 2025 [176]. - The company plans to submit the MyoVista wavECG device for FDA clearance under the 510(k) pathway in calendar 2025 [170]. - The company aims for an FDA submission of a low-ejection fraction algorithm during the first half of calendar 2026 [170]. Capital and Financing - The company has entered into a Series D Preferred Stock offering with a maximum amount of $15.0 million, priced at $3.50 per unit [178]. - The Company issued 1,556,409 Units consisting of Series D Preferred Stock and Warrants for gross proceeds of approximately $5.4 million as of the date of the Quarterly Report [181]. - The Company expects to continue raising capital through the sale of additional equity securities, debt, or strategic partnerships to fund ongoing operations [204]. Operational Challenges - The company has experienced recurring losses and negative cash flows, raising substantial doubt about its ability to continue as a going concern [172]. - As of January 31, 2025, the company's stockholders' equity was reported at $1,786,689, below the Nasdaq minimum requirement of $2.5 million [173]. - Selling, general, and administrative expenses increased by $27,000, or 3%, to approximately $878,000 for the three months ended July 31, 2025, mainly due to increased stock compensation expense [195]. - Interest expense rose to $184,000 for the three months ended July 31, 2025, an increase of $161,000 or 715% compared to the same period in 2024 [196]. Accounting and Reporting - No material changes to critical accounting policies and estimates from the 2025 Annual Report on Form 10-K [211]. - Smaller reporting company is not required to provide quantitative and qualitative disclosures about market risk [212].

Core Viewpoint - HeartSciences Inc. is actively engaging with investors through multiple virtual events in August 2025 to showcase its AI-powered ECG technology aimed at early heart disease detection [1][2][3] Group 1: Upcoming Events - The company will host an Investor Webinar on August 20, 2025, at 2:00 PM Eastern Time, providing an overview of its mission, market opportunity, and recent progress [2] - HeartSciences will also present at the Emerging Growth Conference 85 on the same day at 3:10 PM Eastern Time, allowing real-time interaction with investors [3] - Archived webcasts of these events will be available for those unable to attend live [4] Group 2: Company Overview - HeartSciences focuses on enhancing the clinical utility of ECGs through innovative AI technology, aiming to improve cardiac screening, especially in frontline clinical settings [5] - The company possesses one of the largest libraries of AI-ECG algorithms and plans to offer these through a cloud-based solution and a low-cost ECG hardware platform [5] - The MyoVista® wavECG™, the company's first product candidate for FDA clearance, is designed to provide diagnostic information related to cardiac dysfunction alongside conventional ECG data [5]

[Form 8-K Current Report: HeartSciences Inc.](index=1&type=section&id=Form%208-K%20Current%20Report%3A%20HeartSciences%20Inc.) [Item 2.02 Results of Operations and Financial Condition](index=3&type=section&id=Item%202.02%20Results%20of%20Operations%20and%20Financial%20Condition) HeartSciences Inc. announced its fiscal year 2025 financial and operating results on July 24, 2025, via a press release furnished as Exhibit 99.1, which is not considered 'filed' for regulatory liability purposes - The company issued a press release on July 24, 2025, to provide financial and operating results for the fiscal year ended April 30, 2025[7](index=7&type=chunk) - The press release is attached as Exhibit 99.1 and is incorporated by reference into this report[7](index=7&type=chunk) - Information in this item and the attached exhibit is not considered "filed" for Section 18 of the Securities Exchange Act of 1934 liability purposes[8](index=8&type=chunk) [Item 9.01 Financial Statements and Exhibits](index=3&type=section&id=Item%209.01%20Financial%20Statements%20and%20Exhibits) This section lists the exhibits accompanying the Current Report, primarily the July 24, 2025 press release (99.1) and an Interactive Data File (104) Exhibits Filed | Exhibit No. | Description | | :--- | :--- | | 99.1* | Press Release dated July 24, 2025 | | 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

Core Viewpoint - HeartSciences Inc. is advancing its AI-powered ECG technology to enhance heart disease detection and aims for commercialization in 2026, pending regulatory approvals [1][6]. Fiscal 2025 and Business Highlights - The company made significant strategic advancements in fiscal year 2025, focusing on enhancing the clinical value of ECGs through AI and cloud technologies applicable in various healthcare settings [2]. - HeartSciences launched the MyoVista Insights software platform, designed to modernize ECG management and integrate with existing hospital systems, facilitating access to AI-ECG algorithms [6][7]. MyoVista Insights™ Software Platform - MyoVista Insights aims to become the first cloud-native ECG management software, targeting a multibillion-dollar market by replacing outdated systems [6]. - The platform began rollout in May 2025, with plans for a second phase alongside the FDA submission of a cloud-based algorithm for detecting reduced ejection fraction in 2026 [6]. MyoVista® wavECG™ Device - The company is nearing FDA submission for the MyoVista wavECG device, with final testing nearly complete [6]. - The device incorporates an algorithm for impaired cardiac relaxation that aligns with updated guidelines from the American Society of Echocardiography [6]. Financial Results - HeartSciences reported no significant revenue for fiscal year 2025, with approximately $1.1 million in cash and $0.2 million in shareholders' equity as of April 30, 2025 [8]. - The company raised $3.1 million in gross proceeds through a Reg A+ offering and converted $0.9 million of debt into equity, strengthening its balance sheet [11]. Regulatory and Market Developments - The Centers for Medicare & Medicaid Services approved reimbursement for AI-ECG algorithms at $128 per test, in addition to standard ECG reimbursement [6]. - The FDA granted "Breakthrough Device" designation for HeartSciences' aortic stenosis ECG algorithm, indicating significant potential in the market [6]. Intellectual Property and Partnerships - HeartSciences expanded its intellectual property portfolio, holding 44 granted patents worldwide, including a key patent for estimating echocardiographic parameters via ECG [6]. - The company is growing its institutional clinical partnerships and Scientific Advisory Board to support clinical adoption and development [6].

AI and Product Development - The company is focused on developing AI-based ECG algorithms to enhance the clinical utility of ECGs for detecting a broader range of heart diseases [19]. - The MyoVista wavECG device is a proprietary 12-lead ECG that integrates AI-ECG algorithms to provide diagnostic information related to cardiac dysfunction [19]. - The company entered into license agreements with Icahn School of Medicine at Mount Sinai to commercialize AI-ECG algorithms for various cardiovascular conditions [21]. - The company received Breakthrough Device designation from the FDA for the aortic stenosis algorithm licensed from Mount Sinai in June 2025 [21]. - The company aims to submit the MyoVista Insights Cloud Platform and low ejection fraction algorithm for FDA clearance in the first half of calendar year 2026 [32]. - The MyoVista Insights Cloud Platform is being developed to provide efficient ECG management, hosting multiple AI-ECG algorithms, and aims to create an AI-ECG marketplace [40]. - The first AI-ECG cloud-based algorithm is expected to be a low ejection fraction algorithm licensed from Mount Sinai, developed using over 100,000 patient records, with a regulatory pathway anticipated to be 510(k) [44]. - The MyoVista wavECG device incorporates a cardiac dysfunction algorithm and features a 12-lead resting ECG capability, designed to detect diastolic dysfunction [48]. - The company is preparing for a 510(k) FDA submission for the MyoVista wavECG device in calendar 2025, following the FDA's new product code for cardiovascular machine learning-based notification software [31]. - The company anticipates expanding its pipeline of AI-ECG algorithms following regulatory clearance of the first algorithm, leveraging relationships with clinical institutions for further development [47]. Market Potential and Financials - Heart disease is the leading cause of death globally, with an estimated 17.9 million deaths from cardiovascular diseases in 2019, representing 32% of all global deaths [33]. - The cost of heart disease in the U.S. was approximately $240 billion annually in 2018 and 2019, including healthcare services, medications, and lost productivity [35]. - The global ECG market is projected to grow from $10.93 billion in 2023 to $30.87 billion by 2034, indicating significant market potential for MyoVista's products [60]. - Approximately 48% of Medicare beneficiaries are enrolled in Medicare Advantage plans, creating a target market for MyoVista's cloud-based and hardware platforms [65]. - The initial revenue model for the MyoVista wavECG device is expected to follow a "razor-razorblade" model, with proprietary electrodes required for each test performed [20]. - The initial revenue model for the MyoVista wavECG device includes capital sales and recurring revenue from proprietary supplies, with a focus on device-agnostic AI-ECG algorithm delivery [67]. - The MyoVista wavECG device is expected to qualify for Medicare reimbursement for existing ECG testing procedures, with interpretation and report ranges from approximately $17 to $55 depending on the healthcare facility type [72]. Regulatory and Compliance Challenges - The company is preparing for a 510(k) FDA submission in calendar 2025 for the MyoVista wavECG device, following a De Novo clearance granted in August 2023 [169]. - The FDA's 510(k) clearance process for medical devices typically takes from three to twelve months, but often takes longer [94]. - The company must comply with stringent QSR requirements during the design and manufacturing process of medical devices [108]. - The FDA has broad regulatory compliance powers, including the ability to impose sanctions such as recalls or fines for non-compliance [110]. - The company previously achieved a CE Mark under the EU Medical Devices Directive in February 2017, which has since lapsed and must now comply with the EU MDR [115]. - The updated CE mark certificate under EU MDR is necessary for the company to market the MyoVista wavECG in the European Economic Area [115]. - The company is subject to extensive government regulation, and failure to comply could harm its business and lead to enforcement actions [132]. - The company faces significant challenges in obtaining regulatory approval for its MyoVista wavECG hardware and associated platforms, which are critical for its business plan [149]. Financial Performance and Risks - The company has incurred significant operating losses, reporting net losses of approximately $8.8 million and $6.6 million for Fiscal 2025 and Fiscal 2024, respectively, with an accumulated deficit of approximately $76.1 million as of April 30, 2025 [136]. - The company anticipates continued significant operating losses for the foreseeable future due to the uncertainties associated with developing medical devices [138]. - There is substantial doubt about the company's ability to continue as a going concern due to recurring losses and limited capital resources, which may adversely affect its share price and ability to raise new capital [164]. - The company may need to raise additional funding, which may not be available on acceptable terms, potentially impacting its development efforts [128]. - Material weaknesses in internal controls over financial reporting have been identified, which could impact the accuracy of financial statements and compliance with stock exchange requirements [157][161]. Competition and Market Dynamics - The company faces intense competition from established players like GE Healthcare, Philips, and Baxter, which have greater brand recognition and resources [191]. - The medical device market, particularly in ECG technologies, is highly competitive, leading to potential price reductions and lower product margins [192]. - If competitors offer significant discounts, the company may need to lower its prices, impacting revenue generation [193]. - The company must continuously enhance its products and develop new technologies to remain competitive in a rapidly changing medical device market [189]. Operational and Management Challenges - The company relies heavily on attracting and retaining skilled personnel, with intense competition for qualified employees in the medical device field [194]. - The management team has limited experience in managing a public company, which may affect compliance with regulatory obligations [197]. - As of July 23, 2025, the company had only 15 full-time employees, making it vulnerable to operational risks if key personnel leave [198]. - Future growth may require additional managerial and operational resources, which could disrupt operations if recruitment challenges arise [195]. External Factors and Risks - The company plans to conduct business outside the U.S., exposing it to various regulatory and economic risks [200]. - Changes in global economic conditions, including inflation and geopolitical events, could adversely affect the company's financial condition and liquidity [205]. - The company’s operations may be impacted by health crises, such as pandemics, which could disrupt manufacturing and supply chains [209]. - Regulatory changes may impose restrictions on operations, leading to higher costs or lower sales for approved products [211]. - Clinical studies are necessary for future product submissions, which are lengthy and costly with uncertain outcomes [213]. - Delays in clinical studies can adversely affect costs, timing, and successful completion, impacting regulatory approval [214].